

1 **In-depth proteomic characterization of *Schistosoma haematobium*: towards the**
2 **development of new tools for elimination**

3 Javier Sotillo^{1*}, Mark S. Pearson¹, Luke Becker¹, Gebeyaw G. Mekonnen¹, Abena S.
4 Amoah², Govert van Dam², Paul L.A.M. Corstjens³, Takafira Mduluza^{4,5}, Francisca
5 Mutapi^{5,6} and Alex Loukas^{1*}

6

7 ¹ Centre for Molecular Therapeutics, Australian Institute of Tropical Health and
8 Medicine, James Cook University, Cairns, Queensland, Australia

9 ² Department of Parasitology, Leiden University Medical Center, Leiden, The
10 Netherlands

11 ³ Department of Molecular Cell and Chemical Biology, Leiden University Medical
12 Center, Leiden, The Netherlands.

13 ⁴ Biochemistry Department, University of Zimbabwe, Mount Pleasant, Harare,
14 Zimbabwe

15 ⁵ TIBA Partnership, NIHR Global Health Research Unit Tackling Infections to
16 Benefit Africa (TIBA), University of Zimbabwe

17 ⁶ Institute of Immunology & Infection Research, School of Biological Sciences,
18 University of Edinburgh, Ashworth Laboratories, King's Buildings, Edinburgh, UK

19

20 * Corresponding authors:

21 Dr Javier Sotillo: javier.sotillo@jcu.edu.au

22 Prof Alex Loukas: alex.loukas@jcu.edu.au

23

24 Short title: Proteomes of *Schistosoma haematobium*

25 **Abstract**

26 Background

27 Schistosomiasis is a neglected disease affecting hundreds of millions worldwide. Of
28 the three main species affecting humans, *Schistosoma haematobium* is the most
29 common, and is the leading cause of urogenital schistosomiasis. *S. haematobium*
30 infection can cause different urogenital clinical complications, particularly in the
31 bladder, and furthermore, this parasite has been strongly linked with squamous cell
32 carcinoma. A comprehensive analysis of the molecular composition of its different
33 proteomes will contribute to developing new tools against this devastating disease.

34

35 Methods and Findings

36 By combining a comprehensive protein fractionation approach consisting of OFFGEL
37 electrophoresis with high-throughput mass spectrometry, we have performed the first
38 in-depth characterisation of the different discrete proteomes of *S. haematobium* that
39 are predicted to interact with human host tissues, including the secreted and
40 tegumental proteomes of adult flukes and secreted and soluble egg proteomes. A total
41 of 662, 239, 210 and 138 proteins were found in the adult tegument, adult secreted,
42 soluble egg and secreted egg proteomes, respectively. In addition, we probed these
43 distinct proteomes with urine to assess urinary antibody responses from naturally
44 infected human subjects with different infection intensities, and identified adult fluke
45 secreted and tegument extracts as being the best predictors of infection.

46

47 Conclusion

48 We provide a comprehensive dataset of proteins from the adult and egg stages of *S.*
49 *haematobium* and highlight their utility as diagnostic markers of infection intensity
50 for the development of novel tools to control this important neglected tropical disease.

51

52

53 **Author Summary**

54 Schistosomiasis is a neglected tropical disease affecting millions of people
55 worldwide. Of the main three species affecting humans, *Schistosoma haematobium* is
56 the most common, and is the leading cause of urogenital schistosomiasis. This
57 parasite can cause a range of clinical complications associated with bladder
58 pathogenesis, including squamous cell carcinoma as well as genital malignancy in
59 women. Herein, we have performed the first comprehensive characterisation of the
60 proteins implicated in host-parasite interactions (secreted and surface proteins from
61 the adult flukes and secreted and soluble egg proteins) in order to advance our
62 understanding of the parasite's biology. Furthermore, we have characterised the
63 different antibody responses in urine from infected human subjects from an endemic
64 area presenting different infection intensities. The data obtained in this study can be
65 used as a first step towards the development of novel tools for the control of
66 urogenital schistosomiasis.

67 **Introduction**

68 Schistosomiasis is a neglected tropical and debilitating disease caused by different
69 trematodes from the genus *Schistosoma* [1]. It affects over 250 million people
70 worldwide, particularly in developing and tropical regions [2-4]. Despite widespread
71 use of the anthelmintic praziquantel in mass drug administration programs over the
72 last 30 years [5], this parasitic infection still causes a loss of 1.9 million disability-
73 adjusted life years (DALYs) [6], and this number could be greater if morbidity
74 associated with asymptomatic infections was included in the calculations [7]. Of the 6
75 species affecting humans, *S. haematobium* is the most common, causing urogenital
76 schistosomiasis in over 100 million people [1], although it is considered the neglected
77 schistosome since the amount of “omics” information is scarce compared to other
78 schistosomes and the difficulty in maintaining the parasite in an animal model [8, 9].
79 *S. haematobium* infection has been reported in 54 countries [10], particularly in sub-
80 Saharan Africa and the Middle East [2, 3]. Furthermore, an outbreak of urogenital
81 schistosomiasis was observed in Corsica (France) [11], although this parasite has
82 recently been shown to be a hybrid between *S. haematobium* and *Schistosoma bovis*.
83 [12].

84

85 The clinical complications associated with urogenital schistosomiasis are linked
86 among others, to bladder pathology [13]. The association between squamous cell
87 carcinoma and *S. haematobium* infection is undisputed [14]; indeed, this blood fluke
88 has been classified as a Class I carcinogen by the International Agency for Research
89 on Cancer (IARC) [15]. Once established in the mesenteric veins surrounding the
90 bladder, *S. haematobium* adult females start laying eggs that pass through the bladder
91 epithelium to be secreted in the urine. However, some eggs get trapped in the bladder

92 wall causing a chronic local inflammation that will develop into a granuloma
93 accompanied by relentless cell proliferation and ultimately in some patients, bladder
94 cancer [16] as well as genital malignancy in women [17, 18]. The initial inflammatory
95 response is thought to be a reaction to mechanical damage caused by passing of eggs
96 through the urothelium (a multilayered epithelium that lines most of the urogenital
97 tract) [13]; however, proteins secreted by parasite eggs have also been shown to
98 increase cell proliferation and angiogenesis [13]. One of the most abundant proteins
99 secreted by *S. haematobium* eggs is the IPSE, or interleukin-4 inducing principle from
100 *Schistosoma mansoni* eggs. IPSE induces cell proliferation and angiogenesis [13, 19],
101 and an IPSE homologue from *S. haematobium* has been shown to attenuate
102 inflammation by stimulating release of IL-4 [19, 20].

103

104 Despite the clear role of soluble egg proteins in the development of granulomas and a
105 carcinogenic environment, the protein composition of this or other *S. haematobium*
106 tissues/organs has not been fully characterised, although a few studies have identified
107 several immunogenic proteins [21]. In contrast, different proteomes from the related
108 species *S. mansoni*, *S. japonicum* and even from the cattle-infecting *S. bovis* have
109 been well characterised [22-26], which has allowed for the identification of novel
110 vaccine and diagnostic antigen candidates. Indeed, different tegumental and secreted
111 proteins are potential vaccine candidates and some have entered or completed Phase I
112 and II clinical trials [27]. The most progressed vaccine candidate for *S. haematobium*
113 infection is glutathione S-transferase (Sh28GST), which completed Phase III clinical
114 testing in 2012 [28] but the results have yet to be published [29].

115

116 Characterising the molecular interface of host-parasite interactions in *S. haematobium*
117 infection is crucial for (i) a better understanding of the parasite's biology and, (ii) for
118 the development of new tools for control and diagnosis. In the present study, we
119 provide the first in-depth identification of secreted and surface proteomes of *S.*
120 *haematobium*. We also characterise the antibody responses in urine from infected
121 human subjects from an endemic area presenting with different infection intensities as
122 a first step towards the development of novel diagnostic tools against this devastating
123 disease.

124

125

126 **Experimental procedures**

127 Ethics

128 The collection of urine from individuals from Zimbabwe was approved by the
129 Medical Research Council of Zimbabwe; Approval MRCZ/A/1710.

130

131 All experimental procedures involving animals reported in the study were approved
132 by the James Cook University (JCU) animal ethics committee (ethics approval
133 number A2391). The study protocols were in accordance with the 2007 Australian
134 Code of Practice for the Care and Use of Animals for Scientific Purposes and the
135 2001 Queensland Animal Care and Protection Act.

136

137 Human *Schistosoma haematobium* parasitology

138 Urine samples from naturally infected individuals were collected on three consecutive
139 days for parasitological examinations. *S. haematobium* infection was detected by
140 microscopic examination of the parasite eggs in 10ml urine, processed using the

141 standard urine filtration method [30]. For each participant, infection intensity was
142 expressed as the arithmetic mean of egg counts per 10 mL urine of samples collected
143 on consecutive days. Urines were stratified according to WHO classification as
144 having either a high (>50 eggs/10 ml of urine), medium (11-49 eggs/10ml of urine) or
145 low (0.3-10 eggs/10 ml of urine) level of infection [31]. Egg negative urines (0
146 eggs/10 ml of urine) were tested for the presence of circulating anodic antigen (CAA
147 – a more sensitive diagnostic test than microscopic detection of eggs in urine) using
148 the UCAA2000 (wet format) as described previously [32] to confirm the presence or
149 absence of infection.

150

151 Parasite material

152 *S. haematobium*-infected *Bulinus truncatus* snails were provided by the National
153 Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource
154 Center for distribution through BEI Resources, NIAID, National Institutes of Health
155 (NIH), USA: *S. haematobium*, Egyptian strain, exposed *B. truncatus* subsp. *truncatus*,
156 NR-21965. Snails were removed from their tank, washed with water and transferred
157 to a petri dish without light or water at 27°C for 90 minutes. They were then rinsed
158 again and water was added to an approx. depth of 3-5 mm. Snails were then placed
159 under direct light maintaining a temperature of 28-30°C for 1-2 hours. The water was
160 then transferred to a new petri dish through a sieve with 20 µm pore size to
161 concentrate cercariae. Water was transferred from the snails to the sieve every 20 min
162 three more times while cercariae continued to be shed. Mice (6 week-old Balb/c) were
163 infected with 1,000 cercariae by tail penetration and adult worms were recovered by
164 vascular perfusion at 16 weeks p.i. [33]. Eggs from livers of perfused mice were

165 isolated according to the method of Dalton et al. [34] to obtain highly purified ova
166 that were free of host debris.

167

168 *Isolation of adult excretory/secretory products*

169 Two hundred freshly perfused adult fluke pairs were washed 3× in serum-free Basch
170 media supplemented with 4× antibiotic/antimycotic (10,000 units/mL of penicillin,
171 10,000 µg/mL of streptomycin, and 25 µg/mL of Amphotericin B) (AA) (Thermo
172 Fisher Scientific, USA) [35] followed by incubation in the same medium at 37°C, 5%
173 CO₂ at a density of ~50 fluke pairs in 4 mL of medium for 7 days. Culture medium
174 was changed after 4 hours and discarded to minimize the presence of host
175 contaminants from regurgitating flukes. Media was subsequently changed every day
176 and dead flukes removed from the plate to avoid contamination with somatic proteins.
177 The excretory/secretory (ES) material was collected each day, centrifuged at 500 g,
178 2,000 g and 4,000 g to remove parasite debris, buffer exchanged in PBS, concentrated
179 using a 10 kDa spin concentrator (Merck Millipore, USA), protein quantified by BCA
180 (Thermo Fisher Scientific, USA), aliquoted and stored at -80°C until use.

181

182 *Tegument extraction*

183 Extraction of tegument proteins from adult flukes was performed using the
184 freeze/thaw/vortex technique as described previously [22, 36]. Briefly, two batches of
185 50 freshly perfused adult fluke pairs were washed 3× in PBS, frozen at -80°C, thawed
186 on ice, washed in TBS (10 mM Tris/HCl, 0.84% NaCl, pH 7.4) and incubated for 5
187 min on ice in 10 mM Tris/HCl, pH 7.4. Each sample was vortexed for 5 × 1 s bursts,
188 the tegument extract pelleted at 1,000 g for 30 min and solubilized three times in 200
189 µl of solubilizing solution (0.1% (w/v) SDS, 1.0% (v/v) Triton X-100 in 40 mM Tris,

190 pH 7.4) with pelleting at 15,000 g between each wash. The washes were combined
191 and buffer exchanged and concentrated as described above.

192

193 *Egg excretory/secretory products and soluble egg antigen*

194 Purified eggs were cultured in serum-free Basch medium supplemented with 4× AA
195 (50,000 eggs/5 ml) for 72 hours at 37°C with 5% CO₂. Medium containing egg ES
196 products was harvested every 24 hours and processed as described for adult ES.
197 Approximately 400,000 eggs were used for ES generation. To obtain SEA, freshly
198 isolated eggs in PBS (100,000/ml) were homogenized in a hand-held Potter-Elvehjem
199 glass homogeniser (15 ml capacity), centrifuged at 200 g for 20 min at 4°C and then
200 the supernatant centrifuged at 100,000 g for 90 min at 4°C [33]. The supernatant was
201 then processed as described for adult ES.

202

203 *OFFGEL electrophoresis*

204 OFFGEL fractionation was performed for adult ES, adult tegument, adult somatic and
205 egg ES samples as described by Sotillo et al. [37]. A total of 100 µg of protein was
206 resuspended in 50 mM NH₄CO₃, 20 mM DTT and incubated at 65°C for 1 h.
207 Alkylation was then achieved by adding iodoacetamide (IAM) to 55 mM and
208 incubating the solution for 40 min in darkness at room temperature (RT). A final
209 incubation with 100 mM DTT was performed at RT before adding 2 µg of trypsin and
210 incubating overnight at 37°C. Fractionation of samples was performed using a 3100
211 OFFGEL fractionator and OFFGEL kit (pH 3–10; 24-well format) (Agilent
212 Technologies, Australia) according to the manufacturer's protocols. Briefly, resultant
213 peptides were diluted in peptide-focusing buffer, 150 µL of sample was loaded into
214 each of the 24 wells and the sample was focused in a current of 50 µA until 50

215 kilovolt hours was reached. Each of the fractions was collected, dried under a vacuum
216 centrifuge and resuspended in 10 μ L of 0.1% TFA before being desalted using a Zip-
217 Tip® (Merck Millipore, USA). Finally, samples were dried again under a vacuum
218 centrifuge and stored at -80°C until use.

219

220 Mass spectrometry

221 Due to limited availability of material because of the difficulty in maintaining *S.*
222 *haematobium* in mice, different numbers of replicates were run for each sample. A
223 total of 48 offgel samples from 2 different replicates (24 samples each) were run for
224 adult ES, 48 offgel samples from 2 different replicates (24 samples each) for adult
225 tegument proteins, 24 offgel samples (from 1 replicate) for egg ES and 2 samples
226 (from 2 replicates) for SEA.

227

228 All samples were analyzed by LC-MS/MS on a Shimadzu Prominence Nano HPLC
229 coupled to a Triple ToF 5600 mass spectrometer (ABSCIEX) using a nano
230 electrospray ion source. Samples were resuspended in 30 μ l of solvent A (0.1%
231 formic acid (aq)) and fifteen μ l was injected onto a 50 mm x 300 μ m C18 trap column
232 (Agilent Technologies) at a rate of 60 μ l/min. The samples were desalted on the trap
233 column for 6 minutes using solvent A at the same rate, and the trap column was then
234 placed in-line with an analytical 150 mm x 100 μ m 300SBC18, 3.5 μ m nano HPLC
235 column (Agilent Technologies) for mass spectrometry analysis. Peptides were eluted
236 in a linear gradient of 2-40% solvent B (90/10 acetonitrile/ 0.1% formic acid (aq))
237 over 80 min at 500 nL/min flow rate after 6 minutes of wash at 2% solvent B and
238 followed by a steeper gradient from 40% to 80% solvent B in 10 min. Solvent B was
239 held at 80% for 5 min for washing the column and returned to 2% solvent B for

240 equilibration prior to the next sample injection. Mass spectrometer settings were:
241 ionspray voltage = 2,200V, declustering potential (DP) = 100V, curtain gas flow = 25,
242 nebuliser gas 1 (GS1) = 12 and interface heater = 150°C. The mass spectrometer
243 acquired 250 ms full scan TOF-MS data followed by 20 by 250 ms full scan product
244 ion data in an Information Dependent Acquisition (IDA) mode. Full scan TOF-MS
245 data was acquired over the mass range 300-1600 and for product ion ms/ms 80-1600.
246 Ions observed in the TOF-MS scan exceeding a threshold of 150 counts and a charge
247 state of +2 to +5 were set to trigger the acquisition of product ion, ms/ms spectra of
248 the resultant 20 most intense ions. The data was acquired using Analyst TF 1.6.1
249 (ABSCIEX).

250

251 Database search and protein identification

252 Peak lists obtained from MS/MS spectra were identified using a combination of five
253 search engines in SearchGUI version v3.3.3 [38] since it has been shown that
254 combining multiple search engines increases the confidence of identified peptide
255 spectrum matches (PSMs), distinct peptide sequences and proteins [39]. The search
256 engines used were: X!Tandem version X! Tandem Vengeance (2015.12.15.2) [40],
257 MS-GF+ version Release (v2018.04.09) [41], Comet version 2018.01 rev. 0 [42],
258 MyriMatch version 2.2.140 [43] and Tide [44].

259

260 Protein identification was conducted against a concatenated target/decoy version of
261 the *S. haematobium* proteome downloaded from Parasite Wormbase (version of 2017-
262 05-WormBase - www.parasite.wormbase.org, 11,140 sequences) and concatenated to
263 the common repository of adventitious proteins (cRAP,
264 <https://www.thegpm.org/crap/>, 116 sequences) and the sequence of an antigen

265 ortholog to *S. mansoni* TSP-2 that was obtained from GenBank (MK238557) (total of
266 11,257 (target) sequences). The decoy sequences were created by reversing the target
267 sequences in SearchGUI. The identification settings were as follows: Trypsin specific
268 with a maximum of 2 missed cleavages, 10.0 ppm as MS1 and 0.2 Da as MS2
269 tolerances; fixed modifications: Carbamidomethylation of C (+57.021464 Da),
270 variable modifications: Deamidation of N (+0.984016 Da), Deamidation of Q
271 (+0.984016 Da), Oxidation of M (+15.994915 Da), fixed modifications during
272 refinement procedure: Carbamidomethylation of C (+57.021464 Da), variable
273 modifications during refinement procedure: Acetylation of protein N-term
274 (+42.010565 Da), Pyrolidone from E (-18.010565 Da), Pyrolidone from Q (-
275 17.026549 Da), Pyrolidone from carbamidomethylated C (-17.026549 Da). All
276 algorithm specific settings are listed in the Certificate of Analysis available in
277 Supplementary Tables 1-4.

278

279 Peptides and proteins were inferred from the spectrum identification results using
280 PeptideShaker version 1.16.27 [45]. PSMs, peptides and proteins were validated at a
281 1.0% False Discovery Rate (FDR) estimated using the decoy hit distribution. All
282 validation thresholds are listed in the Certificate of Analysis available in the
283 Supplementary Tables 1-4. Mass spectrometry data along with the identification
284 results have been deposited to the ProteomeXchange Consortium via the PRIDE
285 partner repository [46] with the dataset identifiers PXD011137 and
286 10.6019/PXD011137.

287

288 *Bioinformatic analysis of proteomic sequence data*

289 The programs Blast2GO v5.2 [47] and HMMER v3.1b1 [48] were used to classify the
290 proteins according to GO categories and Pfam domains respectively. Pfam domains
291 were detected at the $P < 0.01$ threshold for the HMMER software. ReviGO was used to
292 visualise GO terms using semantic similarity-based scatterplots [49]. The UpSetR
293 package (v. 1.3.3) [50] was used to visualise the intersections of proteins between
294 samples by producing UpSetR plots in R.

295

296 Enzyme-linked immunosorbent assay with human urine

297 The urine of infected individuals (n= 98) from an area in Zimbabwe mono-endemic
298 for *S. haematobium* infection was analyzed by ELISA using all *S. haematobium*
299 protein preparations described earlier. Urine from Australian volunteer donors that
300 had never travelled to schistosomiasis endemic areas was used as a negative control
301 (n= 14).

302

303 Polystyrene microtiter plates (Greiner Bio-One, Austria) were coated overnight at 4°C
304 with 50 µl/well of a 5 µg/ml solution of *S. haematobium* adult ES, adult tegument,
305 SEA or egg ES in 0.1 M carbonate coating buffer, pH 9.6. The plates were washed
306 three times with PBS/0.05% Tween20 (PBST) and blocked for two hours at 37°C
307 using 5% skimmed milk in PBST, followed by three wash steps in PBST for 15 min
308 each. Plates were then incubated with 50 µl of urine (diluted 1:5 in PBS) and
309 incubated at 37°C for 1.5 h followed by 3 washes using PBST. Fifty µl of HRP-
310 conjugated polyclonal anti-human IgG (Sigma-Aldrich) was added at dilution of
311 1:5,000 and incubated for 1 hour at 37°C. Finally, plates were washed 3× with PBST
312 and incubated with 3,3',5,5'-tetramethylbenzidine (TMB, Thermo Fisher Scientific,
313 USA) for 10 min at RT in the dark. The reaction was stopped by adding 3 M HCl and

314 absorbance read at 450 nm using a POLARstar Omega spectrophotometer (BMG
315 Labtech, Australia).

316

317 Statistical analysis

318 GraphPad Prism 7.0 was used for statistical analyses. Differences in antibody titers
319 were analysed using the non-parametric Kruskal-Wallis test with Dunn's multiple
320 comparisons test. Receiver Operating Characteristic (ROC) curves were used to
321 calculate sensitivity, specificity and the area under the curve (AUC). The AUC is a
322 global measure of diagnostic accuracy and indicates the probability of accurately
323 identifying true positives, where a value of 0 indicates a perfectly inaccurate test and a
324 value of 1 reflects a perfectly accurate test [51].

325

326

327 **Results**

328 *Schistosoma haematobium* tissue proteomes involved at the host-parasite interface.

329 The proteomes from different parasite extracts involved in host-parasite interactions,
330 such as the adult ES and tegument proteins as well as the egg ES and somatic (SEA)
331 proteins were characterised by LC-MS/MS. To limit the number of false
332 identifications we appended 116 sequences of common contaminants to the *S.*
333 *haematobium* protein database (Bioproject PRJNA78265,
334 www.parasite.wormbase.org/), and only proteins identified with ≥ 2 peptides were
335 considered as positively identified. The extract with the highest number of identified
336 proteins was the adult tegument (662, Supplementary Table 5), followed by adult ES
337 (239, Supplementary Table 6), SEA (210, Supplementary Table 7) and egg ES (138,
338 Supplementary Table 8). The adult tegument sample also had the highest number of

339 unique (only present in this extract) proteins (430), followed by SEA (61), adult ES
340 (48) and egg ES (19) (Fig 1A). Furthermore, adult tegument and adult ES proteins had
341 85 proteins in common, while only 57 proteins were commonly identified in all
342 datasets (Fig 1A).

343

344 The top 25 most abundant proteins in each extract selected based on the spectral count
345 provided a similar profile: 12 proteins were uniquely identified in adult tegument
346 extract, followed by SEA (11) and adult ES and egg ES (8 each) (Fig 1B). Only 3
347 proteins were commonly identified in all datasets (MS3_04307.1, fatty acid binding
348 protein - FABP; MS3_11229.1, triose phosphate isomerase; and MS3_06482.1,
349 glutathione S-transferase - GST) Unique proteins identified from the adult tegument
350 included three hypothetical proteins (MS3_07454.1, MS3_09812.1 and
351 MS3_01840.1), one tetraspanin (*Sh*-TSP-2) and two annexins (MS3_08723.1 and
352 MS3_05924.1), among others (Fig 1B). Among the proteins uniquely identified in
353 SEA, we found two proteins of the glioma pathogenesis related-1 (GLIPR1)
354 subfamily (MS3_11039.1 and MS3_07294.1), IPSE/alpha-1 protein (MS3_10186.1),
355 as well as several enzymes (MS3_08600.1, MS3_10510.1 and MS3_00286.1) (Fig
356 1B). A calcium binding protein (MS3_00183.1), alpha-tubulin (MS3_02314.1),
357 thioredoxin (MS3_09682.1) and a major egg antigen (MS3_11428.1) were the most
358 highly represented proteins uniquely identified in egg ES, while uniquely identified
359 proteins in adult ES included saposin (MS3_02805.1) and thymosin (MS3_03084.1).

360

361 Protein families and functions in the different proteomes of *Schistosoma*
362 *haematobium*.

363 A Pfam analysis was performed on the different proteomes from *S. haematobium* and
364 the top 25 most represented protein families for each dataset were visualized in a
365 heatmap (Fig 2). Five different protein domains (three different EF-hand-like
366 domains, a tetratricopeptide repeat and an AAA domain) were highly represented in
367 all proteomes, while three domains were exclusively found in proteins identified in
368 the tegument of *S. haematobium* (ADP-ribosylation, Ras family and Ras of Complex
369 Roc) (Fig 2). Similarly, one domain was found in proteins exclusively identified in
370 the egg ES (KH domain), while other cytoskeletal and redox domains (e.g. redoxin,
371 tropomyosin and glutathione S-transferase) were more abundant in proteins from egg
372 ES and SEA. Interestingly, two immunoglobulin domains were highly represented in
373 the proteins identified from the adult ES and also found in the adult tegument but not
374 present in any of the egg proteomes (Fig 2).

375

376 The GO analysis was performed using Blast2GO [47] and biological processes and
377 molecular functions plotted using ReviGO [49]. Several metabolic processes were
378 highly represented in adult ES (Supplementary Table 9), together with
379 “gluconeogenesis” and “proteolysis” (Fig 3A). An “oxidation-reduction process” was
380 common between adult ES and tegument proteomes, while the tegument proteins
381 were also involved in “phosphorylation” (Fig 3C, Supplementary Table 10).
382 Regarding molecular functions inferred from adult ES and tegument proteins, both
383 datasets were enriched in “oxidoreductase activity”, “ATP binding”, “transferase
384 activity” and “cytoskeletal protein binding”, although presenting different scores and
385 frequencies (Fig 3C, D).

386

387 Both egg ES and SEA had distinct profiles with regards to the terms associated with
388 biological process (Supplementary Tables 11 and 12, respectively). Despite both
389 proteomes contain proteins involved in “gluconeogenesis” and “proteolysis”, they had
390 different associated metabolic processes (Fig 4A, C). Two molecular function terms
391 were similar among all proteomes (“oxidoreductase activity”, “ATP binding”), while
392 “protein binding” was exclusively found in egg ES and SEA (Fig 4B, D). In addition,
393 the egg ES proteome was enriched in proteins involved in “kinase activity” and
394 “calcium ion binding”, while the molecular functions in SEA proteins related to
395 “transferase activity” and “metal ion binding” (Fig 4B, D).

396

397

398 *Schistosoma haematobium* secreted and tegument proteins have potential as
399 diagnostic markers of infection.

400 Using the different *S. haematobium* proteomes characterized in this study, we
401 analyzed antibody responses in the urine of *S. haematobium*-infected individuals (Fig
402 5A-D) to the various parasite extracts. Furthermore, the AUC generated from the
403 ROC curves were used to determine the sensitivity and specificity of each antibody
404 response, and the predictive value of infection (Fig 6A-D). Antibodies to all extracts
405 were significantly reactive in the urine of all subjects with a high egg count (>50
406 eggs/ml) compared to non-endemic negative controls with the most significant
407 reactivity being to adult fluke ES and SEA ($p < 0.0001$), although adult tegument and
408 egg ES samples were also highly reactive ($p < 0.001$). Antibodies in the urine of
409 subjects with a medium intensity infection (11-50 eggs/ml) significantly reacted to all
410 extracts, compared to non-endemic negative controls, with the most significant
411 reactivity being to adult ES and tegument extracts ($p < 0.01$). Interestingly, the

412 antibody levels in the urine of subjects with low intensity infection (0.3-10 eggs/ml)
413 were significantly elevated only for adult ES ($p < 0.05$) and not for other extracts
414 tested, while subjects with a very low level of infection (egg-negative by microscopy
415 but CAA-positive) had significantly elevated antibody levels to only adult tegument
416 and SEA extracts ($p < 0.05$).

417

418 The highest predictive value of infection in subjects with a high egg count was
419 generated by the antibody response to adult ES (AUC 0.9954), followed by adult
420 tegument (0.977), egg ES (0.9288) and SEA (0.9101) antibody responses. In the case
421 of subjects with a medium egg count, the highest predictive value of infection was
422 also observed with adult ES antibody responses (0.9707), followed by adult tegument
423 (0.8661), SEA (0.7691) and egg ES (0.7449). This was again the case for subjects
424 with a low egg count; the predictive value of infection for adult ES, adult tegument,
425 SEA and egg ES antibody responses being 0.7612, 0.6518, 0.702 and 0.5435,
426 respectively. Interestingly, the highest predictive value of infection in microscopy egg
427 negative but CAA positive subjects was generated with the antibody response to adult
428 tegument extract (0.9762), followed by SEA (0.869), adult ES (0.8333) and egg ES
429 (0.5357).

430

431

432 **Discussion**

433 Despite accounting for almost two-thirds of all cases of schistosomiasis [52], *S.*
434 *haematobium* remains the most neglected schistosome of medical importance in terms
435 of laboratory research effort, partly due to the lack of proteomic and genomic
436 information (which underpin knowledge of the parasite's biological and pathogenic

437 processes) [8]. Several versions of the *S. mansoni* genome have been published [53,
438 54], as well as numerous high-throughput proteomes from different life stages [22,
439 24-26, 55, 56]; however, only one version of the genome and very few proteins have
440 been characterised for the causative agent of urinary schistosomiasis [57]. Indeed, a
441 thorough examination of the *S. haematobium* genome failed to detect the presence of
442 a homologue of *Sm-TSP-2* in this parasite, despite this protein being found in the
443 proteomic datasets described herein, its abundance in *S. mansoni* proteomes [58] and
444 the presence of numerous homologs in *S. japonicum* [59]. *Sm-TSP-2* has proven to be
445 one of the most effective vaccine candidates against schistosomiasis [60, 61] and has
446 successfully undergone a phase I clinical trial [62]; confirmation of the existence of a
447 *S. haematobium* orthologue is important, therefore, to determine whether a similar (or
448 existing) vaccination strategy might be effective against this species of schistosome.
449 This example highlights the importance of the availability of proteomic data to
450 complement and, as is being increasingly reported, re-annotate existing genomes to
451 provide a comprehensive picture of the makeup of an organism [86].

452

453 Proteins at the interface between the host and the parasite are believed to play a key
454 role in host immune system modulation and parasite survival [63] and so
455 characterisation of these molecules is desirable to further our knowledge of parasite
456 biology and pathogenesis and intervention targets. For example, the proteins secreted
457 and located on/in the tegument of the blood-dwelling adult fluke are immune-
458 accessible, and egg ES molecules are involved in the generation of a tumorigenic
459 environment [13] and can be studied to gain insight into host pathogenesis.

460

461 A total of 57 proteins were commonly identified in all proteomic datasets generated.
462 Among these, MS3_04307.1 (FABP), MS3_11229.1 (triose phosphate isomerase) and
463 MS3_06482 (GST) were highly abundant. All proteomes were enriched in three
464 main protein families: AAA domains, EF-hand like domains and tetratricopeptide
465 repeat (TPR) domains. The high abundance of proteins containing these domains
466 suggests a vital role for these motifs in parasite development and/or survival. While
467 AAA domain-containing proteins such as dyneins participate in a variety of functions
468 and are ubiquitously present in many organisms [64], EF-hand domain proteins are
469 expressed almost uniquely by parasitic worms (highly abundant in trematodes), and
470 have been suggested to be an effective drug target [65]. TPR is a structural repeat
471 found in diverse proteins. In *Schistosoma mekongi* it is present within an O-
472 glycosyltransferase that is abundantly expressed by female flukes [66], while in *S.*
473 *japonicum*, the protein SJCHGC06661 was the highest immunoreactive protein in a
474 protein array screened against the serum from *S. japonicum* infected patients. This
475 protein contains six TPR domains, interacts with the heat shock protein (HSP)
476 complex and has been suggested as a potential drug or vaccine target [67].
477
478 The most complex mixture of proteins was identified in the adult tegument sample
479 (662 proteins). Previous studies on *S. mansoni* schistosomula and *S. japonicum* adult
480 flukes identified 450 and 360 proteins, respectively [22, 68], highlighting the complex
481 composition of this structure, probably due to an adaptive response to living in the
482 harsh environment of the host circulatory system. The molecular functions associated
483 with these proteins correspond to the functions observed in other studies [68]. For
484 instance, proteins involved in several binding functions (the highest represented
485 function in the proteins identified in the *S. japonicum* adult tegument [68]) such as

486 metal ion binding, cytoskeletal protein binding and ATP binding were highly
487 represented in this study. Several molecular functions associated with protection
488 against oxygen-reactive species and redox systems such as oxidoreductase activity
489 and transferase activity were also highly represented, as expected in the tegument of a
490 parasitic helminth which is under constant immune threat [69]. Among the most
491 abundant proteins present in the tegument of *S. haematobium* adult flukes, we
492 identified a putative GPI-anchored protein similar to Sm29 (MS3_03973.1), a
493 tetraspanin similar to *Sm-TSP-2* (*Sh-TSP-2*), an aquaporin (MS3_05757.1), as well as
494 two different annexins (MS3_08723.1 and MS3_05924.1) and several hypothetical
495 proteins (MS3_07454.1, MS3_09812.1 and MS3_01840.1). Sm29 has been shown to
496 be an immunoregulatory molecule able to control inflammatory mucosal diseases with
497 both Th1 and Th2 immune response profiles [70] and can interact with CD59, an
498 inhibitor of the membrane attack complex (MAC), which could contribute to immune
499 evasion [71]. Tetraspanins have a role in maintaining the structure of the tegument
500 and providing stability [72]. Interestingly, Sm29 and *Sm-TSP-2*, as well as the above-
501 mentioned GST and FABP, are important vaccine candidates [27]. Characterising the
502 rest of the identified proteins, particularly the hypothetical proteins, will improve the
503 rational selection of vaccine candidates for *S. haematobium* infection.

504

505 Using an older version of the *S. haematobium* proteome present in WormbaseParasite,
506 only 379 proteins were predicted to be secreted by *S. haematobium*, making it the
507 parasitic helminth with the lowest number of predicted secreted proteins of the 44
508 species assessed [73]. In our analysis, we found 239 proteins in the adult ES products,
509 which accounts for more than 63% of the total predicted secretome. The most
510 abundant domains identified by Cuesta-Astroz in the predicted secretome were

511 PF00053 (Laminin-EGF), which was not highly represented in our analysis, and
512 PF13895 (Immunoglobulin domain), which was one of the most abundant families in
513 the adult ES dataset. We also identified the Immunoglobulin I-set domain as an
514 abundant protein in the adult ES products, which is also one of the most commonly
515 occurring proteins in the predicted helminth secretomes [73], and is present in cell
516 adhesion molecules.

517

518 Egg secretions from trematodes likely result from an active secretion process of the
519 miracidium enclosed within the egg and, in the case of *S. haematobium*, the proteins
520 secreted by the egg might not only reflect the biology of the miracidium stage, but
521 might also be of importance in the development of fibrosis and cancer. Among the top
522 25 most abundant proteins in all datasets, 8 proteins were uniquely identified in the
523 egg secretions, including calcium-binding protein (MS3_00183.1), alpha-tubulin
524 (MS3_02314.1), thioredoxin (MS3_09682.1), polymorphic mucin variant
525 (MS3_01478.1) and the major egg antigen (MS3_11428.1). The calcium-binding
526 protein is orthologous (90% identity) to *S. mansoni* calmodulin, which has been
527 reported as an essential protein for egg development [74]. Indeed, calmodulin
528 inhibitors can disrupt egg hatching and interrupt miracidium transformation into
529 sporocyst [75, 76]. The polymorphic mucin variant has been identified in the
530 miracidium of *S. mansoni* as having a key role in invertebrate host/parasite
531 interactions [77], and a family of *S. mansoni* polymorphic mucins has been
532 hypothesized to act as a smoke-screen blocking pattern recognition receptors, thus
533 avoiding recognition by the host immune system [77].

534

535 Different proteins with a role in defence against oxidative stress, such as GST and
536 thioredoxin, were abundant in the egg ES proteome; as well as two triose phosphate
537 isomerases, which are proteins implicated in glycolysis and energy production.
538 Interestingly, two homologs of programmed cell death protein 5 (PCDC5;
539 MS3_11526.1) and the major egg antigen also known as Smp40 (MS3_11428.1) were
540 also uniquely identified in the egg ES and are among the top 25 most abundant
541 proteins. PCDC5 has a wide variety of biological functions, including programmed
542 cell death and immune regulation [78], and a decrease in the levels of this protein has
543 been associated with multiple types of cancers [78]. Smp40 is associated with reduced
544 collagen deposition, decreased fibrosis, and granuloma formation inhibition [79].
545 Active secretion of these two molecules might reflect an effort from the parasite to
546 minimize the potential fibrosis and cell proliferation induced by other proteins present
547 in the egg shell.

548

549 Two GLIPR1 proteins (MS3_11039.1 and MS3_07294.1) were uniquely identified in
550 the SEA dataset and were among the most abundant proteins based on spectrum
551 counting. These proteins belong to the sperm-coating proteins/Tpx1/Ag5/PR-1/Sc7
552 (SCP/TAPS) family, and have been identified in other trematodes including *Fasciola*
553 *hepatica* [80] as well as other helminths [81]. Although the exact function for these
554 proteins is still unknown, this family of proteins is expanded in the genomes and
555 secreted proteomes of clade IV and V nematodes [82-86] and is believed to play
556 specific biological functions in the host including defence against host attack and
557 determination of lifespan [87]. The presence of these proteins in the eggs of *S.*
558 *haematobium* is intriguing and their roles in this life stage warrants exploration.

559

560 The IPSE/alpha-1 glycoprotein (MS3_ 10186.1) is a well characterized molecule from
561 the eggs of *S. mansoni*. It is located in the subshell area of mature eggs [88] and is a
562 potent driver of IL-4-mediated Th2 responses [88-91]. Furthermore, it induces a
563 potent anti-inflammatory response by inducing regulatory B cells to produce IL-10
564 [89]. The *S. haematobium* homolog of IPSE/alpha-1 (H- IPSE) infiltrates host cells
565 and translocate to the nucleus [19] and, interestingly, has been shown to alleviate the
566 symptoms of chemotherapy-induced hemorrhagic cystitis [20].

567

568 With a view to providing the first steps towards the characterisation of novel
569 molecules that could be used for immunodiagnosis of *S. haematobium* infection, we
570 assessed the levels of IgG antibodies present in the urine of patients from an endemic
571 area in Zimbabwe against the different extracts analysed in the study. Even though the
572 presence of antibodies in serum or urine cannot be used to differentiate previous and
573 current infections, the detection of immunoglobulins against parasites is still a useful
574 diagnostic tool for surveillance, and can be helpful for evaluating the effectiveness of
575 control programmes [92]. Antibody detection diagnostics can also be used to
576 complement less sensitive point-of-care (POC) diagnostic tests, such as microscopic
577 detection of eggs in urine, in areas of low transmission. Some efforts have been made
578 to develop highly sensitive and specific tests for *S. haematobium* infection. For
579 instance, diverse parasite proteomes such as SEA, cercarial antigen preparation (CAP)
580 and soluble worm antigen preparation (SWAP) have been tested [93]. In this study,
581 SEA and CAP were more reactive than SWAP, which is in accordance with previous
582 findings [92, 94-96]. The fact that SWAP is not a good extract from a diagnostic point
583 of view could be because it is highly abundant in intracellular proteins that will never
584 be exposed to host antibodies. The detection of antibodies against SEA and SWAP in

585 the urine of human subjects with schistosomiasis has been previously reported [92,
586 95, 96], but the presence and diagnostic utility urine antibodies to adult fluke
587 tegument and ES have not been described. Herein, we highlight the diagnostic
588 capability of arguably more immunologically relevant proteomes, in addition to SEA,
589 to detect antibodies in the urine of infected individuals, and show that the adult fluke
590 ES and tegument preparations were more reactive than SEA for all of the cohorts
591 studied. Antibodies can be detected in urine of subjects infected with both *S. mansoni*
592 and *S. japonicum* (where eggs are passed in the stool instead of urine), so the presence
593 of antibodies in urine of subjects infected with *S. haematobium* is likely due to
594 clearance of IgG from circulation through the kidneys as opposed to vascular leakage
595 due to bladder pathology caused by parasite eggs.

596

597 We have provided the first comprehensive high-throughput analysis of the proteins
598 present in different *S. haematobium* proteomes of importance in host/parasite
599 interactions, thereby facilitating a snapshot of the molecular biology of the parasite
600 and how it interacts with the host. In addition, we have identified adult fluke ES and
601 tegument extracts as best predictors of infection when probed with antibodies from
602 the urine of infected human subjects. This combined study of proteomic
603 characterisation and serodiagnostic analyses provide the first steps towards the
604 characterisation of novel molecules that could serve as tools for the control and
605 evaluation of *S. haematobium* infection in Sub-Saharan Africa.

606 **Acknowledgements**

607 This work was supported by a program grant from the National Health and Medical
608 Research Council (NHMRC) [program grant number 1037304] and a Senior Principal
609 Research fellowship from NHMRC to AL (1117504). The funders had no role in the
610 study design, data collection and analysis, decision to publish, or preparation of the
611 manuscript. The authors thank the study participants, as well as the parents/legal
612 guardians and their teachers in Zimbabwe for their support of this study. They are
613 very grateful for the cooperation of the Ministry of Health and Child Welfare in
614 Zimbabwe. For their technical support, they would like to thank the members of the
615 Department of Biochemistry at the University of Zimbabwe.

616

617

618 **Author contributions**

619 **Conceptualization:** Javier Sotillo, Mark S. Pearson and Alex Loukas.

620 **Resources:** Javier Sotillo, Gebeyaw G. Mekonnen, Luke Becker, Takafira Mduleza
621 and Francisca Mutapi.

622 **Investigation:** Javier Sotillo, Mark S. Pearson, Abena S Amoah, Govert van Dam and
623 Paul L.A.M. Cortsjens.

624 **Formal analysis:** Javier Sotillo.

625 **Writing - original draft:** Javier Sotillo.

626 **Writing – review & editing:** Javier Sotillo, Mark S. Pearson, Francisca Mutapi and
627 Alex Loukas

628

629

630

631 **Figure Legends**

632 **Figure 1. Proteins identified in the different *Schistosoma haematobium***

633 **proteomes.** (A) The numbers and intersections of the identified proteins from

634 different *Schistosoma haematobium* proteomes was visualised using an Upset plot.

635 Connected dots display shared proteins between datasets, and the total number of

636 proteins identified in a particular dataset is indicated in the set size. (B) Venn diagram

637 representing the intersection of the top 25 most abundant proteins from each dataset

638 based on spectrum counting.

639

640 **Figure 2. Pfam analysis.** The top 25 most represented protein families from every

641 proteome analysed were visualised using a heatmap. Values represent the abundance

642 (in percentage) of each protein family relative to the total number of protein families

643 present in each proteome.

644

645 **Figure 3. Gene ontology analysis of the adult excretory/secretory (ES) and**

646 **tegument protein preparations from *Schistosoma haematobium*.** Gene ontologies

647 of proteins from *S. haematobium* adult ES (A, B) and tegument (C, D) were ranked by

648 nodescore (Blast2GO) and plotted using ReviGO. Figure shows Biological Processes

649 (A, C) and Molecular Function (B, D). Semantically similar GO terms plot close

650 together, circle size denotes the frequency of the GO term from the underlying

651 database, and increasing heatmap score signifies increasing nodescore from

652 Blast2GO.

653

654 **Figure 4. Gene ontology analysis of the egg excretory/secretory (ES) and soluble**

655 **egg antigens (SEA) from *Schistosoma haematobium*.** Gene ontologies of proteins

656 from *S. haematobium* egg ES (A, B) and SEA (C, D) were ranked by nodescore
657 (Blast2GO) and plotted using ReviGO. Figure shows Biological Processes (A, C) and
658 Molecular Function (B, D). Semantically similar GO terms plot close together, circle
659 size denotes the frequency of the GO term from the underlying database, and
660 increasing heatmap score signifies increasing nodescore from Blast2GO.

661

662 **Figure 5. Urine antibody levels against different *Schistosoma haematobium***
663 **antigen preparations.** OD values determined by ELISA using urine from individuals
664 with different infection intensities based on egg counts (high, medium, low and egg
665 negative/CAA positive) from an endemic area of Zimbabwe against different
666 proteomes from *S. haematobium*. A control group of urine from non-endemic
667 individuals who had never been infected with *S. haematobium* was included. Adult
668 excretory/secretory (ES) products (A), tegument proteins (B), egg ES (C) and soluble
669 egg antigen (D). Statistical analysis was performed using a non-parametric Kruskal-
670 Wallis test with multiple comparisons by Dunn's post-test. * $P < 0.05$, ** $P < 0.01$,
671 *** $P < 0.001$, **** $P < 0.0001$

672

673 **Figure 6. Receiver operating characteristic (ROC) curves.** Areas under the ROC
674 curve determine the predicative performance of adult excretory/secretory (ES)
675 products (A), tegument proteins (B), egg ES products (C) and soluble egg antigen
676 (SEA) (D) to detect antibodies in the urine of individuals with differing intensities
677 (high, medium, low and egg negative/CAA positive) of *Schistosoma haematobium*
678 infection. A control group of urine from non-endemic individuals who had never been
679 infected with *S. haematobium* was included.

680 **Supporting information Captions**

681 **Table S1.** Certificate of analysis provided by PeptideShaker for the analysis of the
682 *Schistosoma haematobium* adult secreted proteins.

683 **Table S2.** Certificate of analysis provided by PeptideShaker for the analysis of the
684 *Schistosoma haematobium* adult tegumental proteins.

685 **Table S3.** Certificate of analysis provided by PeptideShaker for the analysis of the
686 *Schistosoma haematobium* egg secreted proteins.

687 **Table S4.** Certificate of analysis provided by PeptideShaker for the analysis of the
688 *Schistosoma haematobium* soluble egg antigen proteins.

689 **Table S5.** *Schistosoma haematobium* adult secreted proteins identified using
690 SearchGUI and PeptideShaker.

691 **Table S6.** *Schistosoma haematobium* adult tegumental proteins identified using
692 SearchGUI and PeptideShaker.

693 **Table S7.** *Schistosoma haematobium* egg secreted proteins identified using
694 SearchGUI and PeptideShaker.

695 **Table S8.** *Schistosoma haematobium* soluble egg antigen proteins identified using
696 SearchGUI and PeptideShaker.

697 **Table S9.** Annotation of the *Schistosoma haematobium* adult secreted proteins
698 provided by Blast2GO.

699 **Table S10.** Annotation of the *Schistosoma haematobium* adult tegumental proteins
700 provided by Blast2GO.

701 **Table S11.** Annotation of the *Schistosoma haematobium* egg secreted proteins
702 provided by Blast2GO.

703 **Table S12.** Annotation of the *Schistosoma haematobium* soluble egg antigen proteins
704 provided by Blast2GO.

705 **References**

- 706 1. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN.
707 Schistosomiasis. *Nat Rev Dis Primers*. 2018;4(1):13. Epub 2018/08/11. doi:
708 10.1038/s41572-018-0013-8. PubMed PMID: 30093684.
- 709 2. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis.
710 *Lancet*. 2014;383(9936):2253-64. doi: 10.1016/S0140-6736(13)61949-2. PubMed
711 PMID: 24698483.
- 712 3. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. *Lancet*.
713 2006;368(9541):1106-18. doi: 10.1016/S0140-6736(06)69440-3. PubMed PMID:
714 16997665.
- 715 4. Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, Boussinesq M, et
716 al. The global burden of disease study 2010: interpretation and implications for the
717 neglected tropical diseases. *PLoS Negl Trop Dis*. 2014;8(7):e2865. Epub 2014/07/25.
718 doi: 10.1371/journal.pntd.0002865. PubMed PMID: 25058013; PubMed Central
719 PMCID: PMC4109880.
- 720 5. Rollinson D, Knopp S, Levitz S, Stothard JR, Tchuem Tchuente LA, Garba A,
721 et al. Time to set the agenda for schistosomiasis elimination. *Acta Trop*.
722 2013;128(2):423-40. Epub 2012/05/15. doi: 10.1016/j.actatropica.2012.04.013.
723 PubMed PMID: 22580511.
- 724 6. DALYs GBD, Collaborators H. Global, regional, and national disability-
725 adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy
726 (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the
727 Global Burden of Disease Study 2016. *Lancet*. 2017;390(10100):1260-344. Epub
728 2017/09/19. doi: 10.1016/S0140-6736(17)32130-X. PubMed PMID: 28919118;
729 PubMed Central PMCID: PMC5605707.

- 730 7. King CH. It's Time to Dispel the Myth of "Asymptomatic" Schistosomiasis.
731 PLoS Negl Trop Dis. 2015;9(2):e0003504. doi: 10.1371/journal.pntd.0003504.
732 PubMed PMID: 25695740; PubMed Central PMCID: PMC4335065.
- 733 8. Rinaldi G, Okatcha TI, Popratiloff A, Ayuk MA, Suttiprapa S, Mann VH, et
734 al. Genetic Manipulation of *Schistosoma haematobium*, the Neglected Schistosome.
735 PLoS Negl Trop Dis. 2011;5(10):e1348. doi: 10.1371/journal.pntd.0001348.
- 736 9. Lewis F. Schistosomiasis. Current protocols in immunology. 2001;Chapter
737 19:Unit-19.1. doi: 10.1002/0471142735.im1901s28. PubMed PMID: 18432750.
- 738 10. World Health Organization. Schistosomiasis (WHO, 2017).
- 739 11. Boissier J, Grech-Angelini S, Webster BL, Allienne JF, Huyse T, Mas-Coma
740 S, et al. Outbreak of urogenital schistosomiasis in Corsica (France): an
741 epidemiological case study. Lancet Infect Dis. 2016;16(8):971-9. Epub 2016/05/21.
742 doi: 10.1016/S1473-3099(16)00175-4. PubMed PMID: 27197551.
- 743 12. Kincaid-Smith J, Tracey A, de Carvalho Augusto R, Bulla I, Holroyd N,
744 Rognon A, et al. Whole genome sequencing and morphological analysis of the
745 human-infecting schistosome emerging in Europe reveals a complex admixture
746 between *Schistosoma haematobium* and *Schistosoma bovis* parasites. BioRxiv. 2018.
- 747 13. Ishida K, Hsieh MH. Understanding Urogenital Schistosomiasis-Related
748 Bladder Cancer: An Update. Front Med. 2018;5:223. Epub 2018/08/31. doi:
749 10.3389/fmed.2018.00223. PubMed PMID: 30159314; PubMed Central PMCID:
750 PMC6104441.
- 751 14. Brindley PJ, Loukas A. Helminth infection-induced malignancy. PLoS Pathog.
752 2017;13(7):e1006393. Epub 2017/07/28. doi: 10.1371/journal.ppat.1006393. PubMed
753 PMID: 28750101; PubMed Central PMCID: PMC6104441.

- 754 15. Humans IWGotEoCRt. Biological agents. Volume 100 B. A review of human
755 carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441. Epub
756 2012/11/30. PubMed PMID: 23189750; PubMed Central PMCID:
757 PMCPMC4781184.
- 758 16. Barsoum RS. Urinary schistosomiasis: review. J Adv Res. 2013;4(5):453-9.
759 Epub 2013/09/01. doi: 10.1016/j.jare.2012.08.004. PubMed PMID: 25685452;
760 PubMed Central PMCID: PMCPMC4293885.
- 761 17. Chenault C, Hoang MP. An Unusual Cervical Finding. Arch Pathol Lab Med.
762 2006;130(3):e37-e8. doi: 10.1043/1543-2165(2006)130[e37:AUCF]2.0.CO;2.
- 763 18. Michelle North MD, Irina Dubinchik MD, Adel Hamid MD, Salah Elderiny
764 MD, Raja Sayegh MD. Association Between Cervical Schistosomiasis and Cervical
765 Cancer: A Report of 2 Cases. J Reprod Med. 2003;48(12):4.
- 766 19. Pennington LF, Alouffi A, Mbanefo EC, Ray D, Heery DM, Jardetzky TS, et
767 al. H-IPSE is a pathogen-secreted host nucleus infiltrating protein (infiltrin) expressed
768 exclusively by the *Schistosoma haematobium* egg stage. Infect Immun. 2017. Epub
769 2017/09/20. doi: 10.1128/IAI.00301-17. PubMed PMID: 28923894; PubMed Central
770 PMCID: PMCPMC5695104.
- 771 20. Mbanefo EC, Le L, Pennington LF, Odegaard JI, Jardetzky TS, Alouffi A, et
772 al. Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory
773 protein, for chemotherapy-induced hemorrhagic cystitis. FASEB J. 2018;32(8):4408-
774 19. Epub 2018/04/04. doi: 10.1096/fj.201701415R. PubMed PMID: 29613835;
775 PubMed Central PMCID: PMCPMC6044057.
- 776 21. Mutapi F. Helminth parasite proteomics: from experimental models to human
777 infections. Parasitology. 2012;139(9):1195-204. Epub 2012/03/28. doi:
778 10.1017/S0031182011002423. PubMed PMID: 22455721.

- 779 22. Sotillo J, Pearson M, Becker L, Mulvenna J, Loukas A. A quantitative
780 proteomic analysis of the tegumental proteins from *Schistosoma mansoni*
781 schistosomula reveals novel potential therapeutic targets. *Int J Parasitol.*
782 2015;45(8):505-16. Epub 2015/04/26. doi: 10.1016/j.ijpara.2015.03.004. PubMed
783 PMID: 25910674.
- 784 23. Perez-Sanchez R, Ramajo-Hernandez A, Ramajo-Martin V, Oleaga A.
785 Proteomic analysis of the tegument and excretory-secretory products of adult
786 *Schistosoma bovis* worms. *Proteomics.* 2006;6 Suppl 1:S226-36. Epub 2006/03/03.
787 doi: 10.1002/pmic.200500420. PubMed PMID: 16511809.
- 788 24. Braschi S, Borges WC, Wilson RA. Proteomic analysis of the schistosome
789 tegument and its surface membranes. *Mem Inst Oswaldo Cruz.* 2006;101 Suppl
790 1:205-12. PubMed PMID: 17308771.
- 791 25. Braschi S, Curwen RS, Ashton PD, Verjovski-Almeida S, Wilson A. The
792 tegument surface membranes of the human blood parasite *Schistosoma mansoni*: a
793 proteomic analysis after differential extraction. *Proteomics.* 2006;6(5):1471-82. doi:
794 10.1002/pmic.200500368. PubMed PMID: 16447162.
- 795 26. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface
796 revealed by biotinylation. *Mol Cell Proteomics.* 2006;5(2):347-56. doi:
797 10.1074/mcp.M500287-MCP200. PubMed PMID: 16269422.
- 798 27. Tebeje BM, Harvie M, You H, Loukas A, McManus DP. Schistosomiasis
799 vaccines: where do we stand? *Parasit Vectors.* 2016;9(1):528. Epub 2016/10/08. doi:
800 10.1186/s13071-016-1799-4. PubMed PMID: 27716365; PubMed Central PMCID:
801 PMC5045607.

- 802 28. ClinicalTrials.gov. Efficacy of Vaccine Sh28GST in Association With
803 Praziquantel (PZQ) for Prevention of Clinical Recurrences of *Schistosoma*
804 *haematobium* Pathology (Bilhvax). ClinicalTrials.gov Identifier: NCT00870649.
- 805 29. Riveau G, Deplanque D, Remoué F, Schacht A-M, Vodougnon H, Capron M,
806 et al. Safety and Immunogenicity of rSh28GST Antigen in Humans: Phase 1
807 Randomized Clinical Study of a Vaccine Candidate against Urinary Schistosomiasis.
808 PLS Negl Trop Dis. 2012;6(7):e1704. doi: 10.1371/journal.pntd.0001704.
- 809 30. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-
810 smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo.
811 1972;14(6):397-400. PubMed PMID: 4675644.
- 812 31. World Health Organization. Prevention and control of schistosomiasis and
813 soil-transmitted helminthiasis : World Health Organization/Unicef joint statement. .
814 Geneva : World Health Organization <http://www.who.int/iris/handle/10665/68607>.
815 2004.
- 816 32. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, et
817 al. Tools for diagnosis, monitoring and screening of *Schistosoma* infections utilizing
818 lateral-flow based assays and upconverting phosphor labels. Parasitology.
819 2014;141(14):1841-55. Epub 2014/06/17. doi: 10.1017/S0031182014000626.
820 PubMed PMID: 24932595; PubMed Central PMCID: PMC4265670.
- 821 33. Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang Y-s.
822 Schistosomiasis. Curr Protoc Immunol. 2013;103(1):19.1.1-1.58. doi:
823 10.1002/0471142735.im1901s103.
- 824 34. Dalton JP, Day SR, Drew AC, Brindley PJ. A method for the isolation of
825 schistosome eggs and miracidia free of contaminating host tissues. Parasitology.
826 1997;115 (Pt 1):29-32. Epub 1997/07/01. PubMed PMID: 9226954.

- 827 35. Basch PF. Cultivation of *Schistosoma mansoni* in vitro. I. Establishment of
828 cultures from cercariae and development until pairing. *J Parasitol.* 1981;67(2):179-85.
829 Epub 1981/04/01. PubMed PMID: 7241277.
- 830 36. Roberts SM, MacGregor AN, Vojvodic M, Wells E, Crabtree JE, Wilson RA.
831 Tegument surface membranes of adult *Schistosoma mansoni*: development of a
832 method for their isolation. *Mol Biochem Parasitol.* 1983;9(2):105-27. Epub
833 1983/10/01. PubMed PMID: 6669162.
- 834 37. Sotillo J, Sanchez-Flores A, Cantacessi C, Harcus Y, Pickering D, Bouchery
835 T, et al. Secreted proteomes of different developmental stages of the gastrointestinal
836 nematode *Nippostrongylus brasiliensis*. *Mol Cell Proteomics.* 2014;13(10):2736-51.
837 Epub 2014/07/06. doi: 10.1074/mcp.M114.038950. PubMed PMID: 24994561;
838 PubMed Central PMCID: PMC4188999.
- 839 38. Vaudel M, Barsnes H, Berven FS, Sickmann A, Martens L. SearchGUI: An
840 open-source graphical user interface for simultaneous OMSSA and X!Tandem
841 searches. *Proteomics.* 2011;11(5):996-9. Epub 2011/02/22. doi:
842 10.1002/pmic.201000595. PubMed PMID: 21337703.
- 843 39. Shteynberg D, Nesvizhskii AI, Moritz RL, Deutsch EW. Combining results of
844 multiple search engines in proteomics. *Mol Cell Proteomics.* 2013;12(9):2383-93.
845 Epub 2013/05/31. doi: 10.1074/mcp.R113.027797. PubMed PMID: 23720762;
846 PubMed Central PMCID: PMC3769318.
- 847 40. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra.
848 *Bioinformatics.* 2004;20(9):1466-7. Epub 2004/02/21. doi:
849 10.1093/bioinformatics/bth092. PubMed PMID: 14976030.
- 850 41. Kim S, Pevzner PA. MS-GF+ makes progress towards a universal database
851 search tool for proteomics. *Nat Commun.* 2014;5:5277. Epub 2014/11/02. doi:

852 10.1038/ncomms6277. PubMed PMID: 25358478; PubMed Central PMCID:
853 PMCPMC5036525.

854 42. Eng JK, Jahan TA, Hoopmann MR. Comet: an open-source MS/MS sequence
855 database search tool. *Proteomics*. 2013;13(1):22-4. Epub 2012/11/14. doi:
856 10.1002/pmic.201200439. PubMed PMID: 23148064.

857 43. Tabb DL, Fernando CG, Chambers MC. MyriMatch: highly accurate tandem
858 mass spectral peptide identification by multivariate hypergeometric analysis. *J*
859 *Proteome Res*. 2007;6(2):654-61. Epub 2007/02/03. doi: 10.1021/pr0604054.
860 PubMed PMID: 17269722; PubMed Central PMCID: PMCPMC2525619.

861 44. Diament BJ, Noble WS. Faster SEQUEST searching for peptide identification
862 from tandem mass spectra. *J Proteome Res*. 2011;10(9):3871-9. Epub 2011/07/19.
863 doi: 10.1021/pr101196n. PubMed PMID: 21761931; PubMed Central PMCID:
864 PMCPMC3166376.

865 45. Vaudel M, Burkhart JM, Zahedi RP, Oveland E, Berven FS, Sickmann A, et
866 al. PeptideShaker enables reanalysis of MS-derived proteomics data sets. *Nat*
867 *Biotechnol*. 2015;33(1):22-4. Epub 2015/01/13. doi: 10.1038/nbt.3109. PubMed
868 PMID: 25574629.

869 46. Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, Foster JM, et al.
870 The PRoteomics IDentifications (PRIDE) database and associated tools: status in
871 2013. *Nucleic Acids Res*. 2013;41(Database issue):D1063-9. Epub 2012/12/04. doi:
872 10.1093/nar/gks1262. PubMed PMID: 23203882; PubMed Central PMCID:
873 PMCPMC3531176.

874 47. Conesa A, Gotz S, Garcia-Gomez JM, Terol J, Talon M, Robles M. Blast2GO:
875 a universal tool for annotation, visualization and analysis in functional genomics

- 876 research. *Bioinformatics*. 2005;21(18):3674-6. doi: 10.1093/bioinformatics/bti610.
877 PubMed PMID: 16081474.
- 878 48. Finn RD, Clements J, Eddy SR. HMMER web server: interactive sequence
879 similarity searching. *Nucleic Acids Res*. 2011;39(Web Server issue):W29-W37. doi:
880 10.1093/nar/gkr367. PubMed PMID: PMC3125773.
- 881 49. Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO Summarizes and
882 Visualizes Long Lists of Gene Ontology Terms. *PLoS One*. 2011;6(7):e21800. doi:
883 10.1371/journal.pone.0021800.
- 884 50. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the
885 visualization of intersecting sets and their properties. *Bioinformatics*.
886 2017;33(18):2938-40. Epub 2017/06/25. doi: 10.1093/bioinformatics/btx364. PubMed
887 PMID: 28645171; PubMed Central PMCID: PMC5870712.
- 888 51. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the
889 receiver-operating characteristic analysis for diagnostic tests. *Prev Vet Med*.
890 2000;45(1-2):23-41. Epub 2000/05/10. PubMed PMID: 10802332.
- 891 52. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD,
892 Habbema JDF, et al. Quantification of clinical morbidity associated with schistosome
893 infection in sub-Saharan Africa. *Acta Tropica*. 2003;86(2):125-39. doi:
894 [https://doi.org/10.1016/S0001-706X\(03\)00029-9](https://doi.org/10.1016/S0001-706X(03)00029-9).
- 895 53. Protasio AV, Tsai IJ, Babbage A, Nichol S, Hunt M, Aslett MA, et al. A
896 Systematically Improved High Quality Genome and Transcriptome of the Human
897 Blood Fluke *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2012;6(1):e1455. doi:
898 10.1371/journal.pntd.0001455.

- 899 54. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, et
900 al. The genome of the blood fluke *Schistosoma mansoni*. Nature. 2009;460:352. doi:
901 10.1038/nature08160
902 <https://www.nature.com/articles/nature08160#supplementary-information>.
- 903 55. Cass CL, Johnson JR, Califf LL, Xu T, Hernandez HJ, Stadecker MJ, et al.
904 Proteomic Analysis of *Schistosoma mansoni* Egg Secretions. Mol Biochem Parasitol.
905 2007;155(2):84-93. doi: 10.1016/j.molbiopara.2007.06.002. PubMed PMID:
906 PMC2077830.
- 907 56. Figueiredo BC-P, Ricci ND, de Assis NRG, de Morais SB, Fonseca CT,
908 Oliveira SC. Kicking in the Guts: *Schistosoma mansoni* Digestive Tract Proteins are
909 Potential Candidates for Vaccine Development. Front Immunol. 2015;6:22. doi:
910 10.3389/fimmu.2015.00022. PubMed PMID: PMC4309203.
- 911 57. Young ND, Jex AR, Li B, Liu S, Yang L, Xiong Z, et al. Whole-genome
912 sequence of *Schistosoma haematobium*. Nat Genet. 2012;44:221. doi:
913 10.1038/ng.1065
914 <https://www.nature.com/articles/ng.1065#supplementary-information>.
- 915 58. Castro-Borges W, Simpson DM, Dowle A, Curwen RS, Thomas-Oates J,
916 Beynon RJ, et al. Abundance of tegument surface proteins in the human blood fluke
917 *Schistosoma mansoni* determined by QconCAT proteomics. J Proteom.
918 2011;74(9):1519-33. doi: <https://doi.org/10.1016/j.jprot.2011.06.011>.
- 919 59. Cai P, Bu L, Wang J, Wang Z, Zhong X, Wang H. Molecular characterization
920 of *Schistosoma japonicum* tegument protein tetraspanin-2: Sequence variation and
921 possible implications for immune evasion. Biochem Biophys Res Commun.
922 2008;372(1):197-202. doi: <https://doi.org/10.1016/j.bbrc.2008.05.042>.

- 923 60. Pearson MS, Pickering DA, McSorley HJ, Bethony JM, Tribolet L, Dougall
924 AM, et al. Enhanced Protective Efficacy of a Chimeric Form of the Schistosomiasis
925 Vaccine Antigen Sm-TSP-2. PLoS Negl Trop Dis. 2012;6(3):e1564. doi:
926 10.1371/journal.pntd.0001564.
- 927 61. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al.
928 Tetraspanins on the surface of *Schistosoma mansoni* are protective antigens against
929 schistosomiasis. Nat Med. 2006;12:835. doi: 10.1038/nm1430
930 <https://www.nature.com/articles/nm1430#supplementary-information>.
- 931 62. Merrifield M, Hotez PJ, Beaumier CM, Gillespie P, Strych U, Hayward T, et
932 al. Advancing a vaccine to prevent human schistosomiasis. Vaccine.
933 2016;34(26):2988-91. doi: <https://doi.org/10.1016/j.vaccine.2016.03.079>.
- 934 63. Sotillo J, Toledo R, Mulvenna J, Loukas A. Exploiting Helminth-Host
935 Interactomes through Big Data. Trends Parasitol. 2017;33(11):875-88. doi:
936 <https://doi.org/10.1016/j.pt.2017.06.011>.
- 937 64. Erzberger JP, Berger JM. Evolutionary relationships and structural
938 mechanisms of aaa+ proteins. Annu Rev Biophys Biomol Struct. 2006;35(1):93-114.
939 doi: 10.1146/annurev.biophys.35.040405.101933.
- 940 65. Thomas Charlotte M, Timson David J. A mysterious family of calcium-
941 binding proteins from parasitic worms. Biochem Soc Trans. 2016;44(4):1005.
- 942 66. Phuphisut O, Ajawatanawong P, Limpanont Y, Reamtong O, Nuamtanong S,
943 Ampawong S, et al. Transcriptomic analysis of male and female *Schistosoma mekongi*
944 adult worms. Parasit Vectors. 2018;11(1):504. doi: 10.1186/s13071-018-3086-z.
- 945 67. Chen J-H, Zhang T, Ju C, Xu B, Lu Y, Mo X-J, et al. An integrated
946 immunoproteomics and bioinformatics approach for the analysis of *Schistosoma*

- 947 *japonicum* tegument proteins. J Proteom. 2014;98:289-99. doi:
948 <https://doi.org/10.1016/j.jprot.2014.01.010>.
- 949 68. Zhang M, Hong Y, Han Y, Han H, Peng J, Qiu C, et al. Proteomic Analysis of
950 Tegument-Exposed Proteins of Female and Male *Schistosoma japonicum* Worms. J
951 Proteome Res. 2013;12(11):5260-70. doi: 10.1021/pr400476a.
- 952 69. Zarowiecki M, Berriman M. What helminth genomes have taught us about
953 parasite evolution. Parasitology. 2015;142(Suppl 1):S85-S97. doi:
954 10.1017/S0031182014001449. PubMed PMID: PMC4413821.
- 955 70. Oliveira SC, Figueiredo BC, Cardoso LS, Carvalho EM. A double edged
956 sword: *Schistosoma mansoni* Sm29 regulates both Th1 and Th2 responses in
957 inflammatory mucosal diseases. Mucosal Immunol. 2016;9:1366. doi:
958 10.1038/mi.2016.69.
- 959 71. White Bear J, Long T, Skinner D, McKerrow JH. Predictions of novel
960 *Schistosoma mansoni* - human protein interactions consistent with experimental data.
961 Sci Rep. 2018;8(1):13092. doi: 10.1038/s41598-018-31272-1.
- 962 72. Tran MH, Freitas TC, Cooper L, Gaze S, Gatton ML, Jones MK, et al.
963 Suppression of mRNAs Encoding Tegument Tetraspanins from *Schistosoma mansoni*
964 Results in Impaired Tegument Turnover. PLoS Pathog. 2010;6(4):e1000840. doi:
965 10.1371/journal.ppat.1000840.
- 966 73. Cuesta-Astroz Y, Oliveira FSd, Nahum LA, Oliveira G. Helminth secretomes
967 reflect different lifestyles and parasitized hosts. Int J Parasitol. 2017;47(9):529-44.
968 doi: <https://doi.org/10.1016/j.ijpara.2017.01.007>.
- 969 74. Taft AS, Yoshino TP. Cloning and Functional Characterization of Two
970 Calmodulin Genes During Larval Development in the Parasitic Flatworm
971 *Schistosoma mansoni*. J Parasitol. 2011;97(1):72-81. doi: 10.1645/GE-2586.1.


- 972 75. Katsumata T, Kohno S, Yamaguchi K, Hara K, Aoki Y. Hatching of
973 *Schistosoma mansoni* eggs is a Ca²⁺/calmodulin-dependent process. Parasitology
974 Research. 1989;76(1):90-1. doi: 10.1007/BF00931079.
- 975 76. Kawamoto F, Shozawa A, Kumada N, Kojima K. Possible roles of cAMP and
976 Ca²⁺ in the regulation of miracidial transformation in *Schistosoma mansoni*. Parasitol
977 Res. 1989;75(5):368-74. doi: 10.1007/BF00931132.
- 978 77. Roger E, Grunau C, Pierce RJ, Hirai H, Gourbal B, Galinier R, et al.
979 Controlled Chaos of Polymorphic Mucins in a Metazoan Parasite (*Schistosoma*
980 *mansoni*) Interacting with Its Invertebrate Host (*Biomphalaria glabrata*). PLoS Negl
981 Trop Dis. 2008;2(11):e330. doi: 10.1371/journal.pntd.0000330.
- 982 78. Li G, Ma D, Chen Y. Cellular functions of programmed cell death 5. Biochim
983 Biophys Acta Mol Cell Res. 2016;1863(4):572-80. doi:
984 <https://doi.org/10.1016/j.bbamcr.2015.12.021>.
- 985 79. Abouel-Nour MF, Lotfy M, Attallah AM, Doughty BL. *Schistosoma mansoni*
986 major egg antigen Smp40: molecular modeling and potential immunoreactivity for
987 anti-pathology vaccine development. Mem Inst Oswaldo Cruz. 2006;101:365-72.
- 988 80. Di Maggio LS, Tirloni L, Pinto AFM, Diedrich JK, Yates Iii JR, Benavides U,
989 et al. Across intra-mammalian stages of the liver fluke *Fasciola hepatica*: a
990 proteomic study. Sci Rep. 2016;6:32796. doi: 10.1038/srep32796
991 <https://www.nature.com/articles/srep32796#supplementary-information>.
- 992 81. Cantacessi C, Hofmann A, Young ND, Broder U, Hall RS, Loukas A, et al.
993 Insights into SCP/TAPS Proteins of Liver Flukes Based on Large-Scale Bioinformatic
994 Analyses of Sequence Datasets. PLoS One. 2012;7(2):e31164. doi:
995 10.1371/journal.pone.0031164.

- 996 82. Sotillo J, Sanchez-Flores A, Cantacessi C, Harcus Y, Pickering D, Bouchery
997 T, et al. Secreted proteomes of different developmental stages of the gastrointestinal
998 nematode *Nippostrongylus brasiliensis*. Mol Cell Proteomics. 2014;13(10):2736-51.
999 doi: 10.1074/.
- 1000 83. Tang YT, Gao X, Rosa BA, Abubucker S, Hallsworth-Pepin K, Martin J, et al.
1001 Genome of the human hookworm *Necator americanus*. Nat Genet. 2014;46(3):261-9.
1002 doi: 10.1038/ng.2875. PubMed PMID: 24441737; PubMed Central PMCID:
1003 PMC3978129.
- 1004 84. Morante T, Shepherd C, Constantinoiu C, Loukas A, Sotillo J. Revisiting the
1005 *Ancylostoma caninum* Secretome Provides New Information on Hookworm–Host
1006 Interactions. Proteomics. 2017;17(23-24):1700186. doi: 10.1002/pmic.201700186.
- 1007 85. Hunt VL, Tsai IJ, Coghlan A, Reid AJ, Holroyd N, Foth BJ, et al. The
1008 genomic basis of parasitism in the Strongyloides clade of nematodes. Nat Genet.
1009 2016;48:299. doi: 10.1038/ng.3495
1010 <https://www.nature.com/articles/ng.3495#supplementary-information>.
- 1011 86. Logan J, Manda SS, Choi Y-J, Field M, Eichenberger R, Mulvenna J, et al.
1012 Comprehensive analysis of human hookworm secreted proteins using a
1013 proteogenomic approach. BioRxiv. 2018.
- 1014 87. Cantacessi C, Campbell BE, Visser A, Geldhof P, Nolan MJ, Nisbet AJ, et al.
1015 A portrait of the “SCP/TAPS” proteins of eukaryotes — Developing a framework for
1016 fundamental research and biotechnological outcomes. Biotechnol Adv.
1017 2009;27(4):376-88. doi: <https://doi.org/10.1016/j.biotechadv.2009.02.005>.
- 1018 88. Schramm G, Gronow A, Knobloch J, Wippersteg V, Grevelding CG, Galle J,
1019 et al. IPSE/alpha-1: A major immunogenic component secreted from *Schistosoma*


- 1020 *mansoni* eggs. Mol Biochem Parasitol. 2006;147(1):9-19. doi:
1021 <https://doi.org/10.1016/j.molbiopara.2006.01.003>.
- 1022 89. Haeberlein S, Obieglo K, Ozir-Fazalalikhani A, Chayé MAM, Veninga H, van
1023 der Vlugt LEPM, et al. Schistosome egg antigens, including the glycoprotein
1024 IPSE/alpha-1, trigger the development of regulatory B cells. PLoS Pathog.
1025 2017;13(7):e1006539. doi: 10.1371/journal.ppat.1006539.
- 1026 90. Wuhler M, Balog CIA, Catalina MI, Jones FM, Schramm G, Haas H, et al.
1027 IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs,
1028 expresses the Lewis X motif on core-difucosylated N-glycans. FEBS J.
1029 2006;273(10):2276-92. doi: doi:10.1111/j.1742-4658.2006.05242.x.
- 1030 91. Schramm G, Mohrs K, Wodrich M, Doenhoff MJ, Pearce EJ, Haas H, et al.
1031 Cutting Edge: IPSE/alpha-1, a Glycoprotein from *Schistosoma mansoni* Eggs, Induces
1032 IgE-Dependent, Antigen-Independent IL-4 Production by Murine Basophils In Vivo.
1033 J Immunol. 2007;178(10):6023.
- 1034 92. Elhag SM, Abdelkareem EA, Yousif AS, Frah EA, Mohamed AB. Detection
1035 of schistosomiasis antibodies in urine patients as a promising diagnostic maker. Asian
1036 Pac J Trop Biomed. 2011;4(10):773-7. doi: [https://doi.org/10.1016/S1995-](https://doi.org/10.1016/S1995-7645(11)60192-2)
1037 [7645\(11\)60192-2](https://doi.org/10.1016/S1995-7645(11)60192-2).
- 1038 93. Nausch N, Dawson EM, Midzi N, Mduluzi T, Mutapi F, Doenhoff MJ. Field
1039 evaluation of a new antibody-based diagnostic for *Schistosoma haematobium* and *S.*
1040 *mansoni* at the point-of-care in northeast Zimbabwe. BMC Infect Dis.
1041 2014;14(1):165. doi: 10.1186/1471-2334-14-165.
- 1042 94. Milner T, Reilly L, Nausch N, Midzi N, Mduluzi T, Maizels R, et al.
1043 Circulating cytokine levels and antibody responses to human *Schistosoma*

1044 *haematobium*: IL-5 and IL-10 levels depend upon age and infection status. Parasite
1045 Immunol. 2010;32(11 - 12):710-21. doi: 10.1111/j.1365-3024.2010.01235.x.
1046 95. Song HB, Kim J, Jin Y, Lee JS, Jeoung HG, Lee YH, et al. Comparison of
1047 ELISA and Urine Microscopy for Diagnosis of *Schistosoma haematobium* Infection. J
1048 Korean Med Sci. 2018;33(33):e238.
1049 96. Itoh M, Ohta N, Kanazawa T, Nakajima Y, Minai M, Daren Z, et al. A tool for
1050 surveillance of schistosomiasis japonica. 1996. Southeast Asian J Trop Med Public
1051 Health 2003, 34(3) 469-472,
1052



A




B




Color Key




A




B




C




D




A




B







C




D







A



B



C



D

